Braveheart Bio, Inc. Common Stock (BRVE) — Working Capital to Net Assets Ratio
Braveheart Bio, Inc. Common Stock (BRVE) has a Working Capital to Net Assets ratio of -119.3% as of June 2026. Working capital of $114.39 Million (current assets of $123.44 Million minus current liabilities of $9.06 Million) is measured against net assets of $-95.91 Million. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Braveheart Bio, Inc. Common Stock Working Capital to Net Assets (2025–2025)
This chart shows how Braveheart Bio, Inc. Common Stock's Working Capital to Net Assets ratio has evolved across 1 annual periods from 2025 to 2025. As of June 2026, the ratio stands at -119.3%, reflecting working capital of $114.39 Million against net assets of $-95.91 Million USD. Read Braveheart Bio, Inc. Common Stock (BRVE) total liabilities for a breakdown of total debt and financial obligations.
Annual Working Capital to Net Assets for Braveheart Bio, Inc. Common Stock (2025–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Braveheart Bio, Inc. Common Stock from 2025 to 2025, covering 1 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see balance sheet size of Braveheart Bio, Inc. Common Stock.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -127.6% | $84.04 Million | $-65.87 Million | $89.28 Million | $5.24 Million | — |